Description
While multiple plasma biomarkers changed in preclinical AD, p-tau231 and p-tau217 showed superior sensitivity to early amyloid accumulation. The molecular basis for this differential performance compared to p-tau181, GFAP, or NfL is not mechanistically explained.
Gap type: unexplained_observation Source paper: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. (2022, Nature medicine, PMID:35953717)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:38.906431+00:00”, “resolution_summary”: “Resolved by hypothesis h-seaad-56fa6428: GFAP-Positive Reactive Astrocyte Subtype Delineation. Supporting evidence includes debate sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-seaad-56fa6428”, “title”: “GFAP-Positive Reactive Astrocyte Subtype Delineation”, “score”: 0.238, “reason”: “25 token overlaps; entity overlap: gfap”, “analysis_id”: “analysis-SEAAD-20260402”, “target_gene”: “GFAP”, “target_pathway”: “Astrocyte Reactivity / A1-A2 Polarization”, “disease”: “Alzheimer’s Disease”, “composite_score”: 0.75408, “confidence_score”: 0.7, “status”: “promoted”, “pubmed_evidence_ids”: [“28709002”, “35143424”, “37824655”, “40680830”, “40911035”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.429, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.39, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.39, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9”, “title”: “The abstract notes that clinical presentations overlap across different myelopathy etiologies, but the mechanistic basis for this convergent phenotype is not explained. Resolving this could improve differential diagnosis and reveal common therapeutic targets.\n\nGap type: unexplained_observation\nSource paper: Uncommon inflammatory/immune-related myelopathies. (2021, J Neuroimmunol, PMID:34715593)”, “score”: 0.382, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9”, “quality_score”: 0.86, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf_task_9aae8fc5”, “title”: “TDP-43 inclusions occur in AD, ALS, and FTLD but the pathogenic mechanisms leading to TDP-43 pathology may differ between diseases. Understanding disease-specific drivers could reveal why TDP-43 shows limbic distribution in AD versus other patterns in ALS/FTLD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.378, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf”, “quality_score”: 0.697, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}